https://doi.org/10.55788/1f2dc080
“The Surviving Sepsis Campaign (SSC) guidelines and Center for Medicare and Medicaid Services (CMS) regulations recommend a bundle of interventions within 3 to 6 hours of sepsis recognition,” said Dr Daniel Leisman (Massachusetts General Hospital, MA, USA) [1]. “However, adherence to these recommendations remains low.” Dr Leisman evaluated whether real-time monitoring and automatic alerts may improve adherence to guideline interventions in patients with suspected sepsis who were at risk for non-adherent care. The included patients (n=1,377) were randomised to the intervention arm, in which an automated reminder page was sent to the physician if a 3-hour bundle element was not completed within 1 hour of the guideline time limit, or to the control group, in which the physicians did not receive automated alerts.
Clinicians ordered a significantly higher number of guideline-directed interventions for patients in the intervention arm than for patients in the control arm (adjusted OR 1.56; 95% CI 1.22–1.99; P=0.0004). As a result, more guideline-adherent care was delivered to patients in the intervention arm (adjusted OR 1.42; P=0.0099). However, there was no significant difference between the 2 study groups concerning mortality at day 28, ICU admissions, or the need for mechanical ventilation.
“Although the alerting system appeared to increase guideline-adherent care delivery in patients with suspected sepsis, this did not lead to a clear reduction in mortality,” summarised Dr Leisman. “The high proportion of patients who discontinued antibiotic treatment early, or had negative cultures, highlights the difficulty in selecting the appropriate patients for sepsis bundle applications.”
- Leisman DE, et al. Effect of automated real-time feedback on early sepsis care: a pragmatic trial. C94, ATS International Conference 2023, 19–24 May, Washington DC, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« The road to improving doctor-patient interactions in kidney cancer Next Article
Mitochondrial DNA levels predict COVID-19 severity »
« The road to improving doctor-patient interactions in kidney cancer Next Article
Mitochondrial DNA levels predict COVID-19 severity »
Table of Contents: ATS 2023
Featured articles
TORREY trial: seralutinib associated with reduced pulmonary vascular resistance in PAH
Practice-changing results for ensifentrine in COPD
Asthma
Vitamin D for asthma protection: what is the optimal timing?
Remarkable results for novel biologic therapy for asthma
Success for fluticasone furoate plus vilanterol in uncontrolled asthma
COPD
Practice-changing results for ensifentrine in COPD
Alvelestat for AATD meets primary endpoints in phase 2 trial
Fewer exacerbations with dupilumab in COPD with type 2 inflammation
New AATD therapy may alleviate treatment burden for patients
Efficient detection of AECOPD with at-home vital signs monitoring
COVID-19
COVA trial: success for the investigational agent sarconeos in hospitalised COVID-19
Mitochondrial DNA levels predict COVID-19 severity
Other
Excellent results for C21 in idiopathic pulmonary fibrosis
Can camlipixant improve quality of life of patients with refractory chronic cough?
TORREY trial: seralutinib associated with reduced pulmonary vascular resistance in PAH
Improving quality care in sepsis through machine learning models
Can information technology improve guideline adherence in sepsis care?
Related Articles
August 17, 2022
CRSwNP outlined
December 25, 2020
One in eight lung-cancer patients have never smoked cigarettes
November 28, 2019
Taxi drivers exposed to highest levels of black carbon pollution
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com